Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities researchers at Zacks Research cut their Q1 2024 earnings per share (EPS) estimates for Esperion Therapeutics in a report released on Tuesday, March 19th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings of ($0.38) per share for the quarter, down from their prior forecast of ($0.36). The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.66) per share. Zacks Research also issued estimates for Esperion Therapeutics' Q2 2024 earnings at ($0.25) EPS, Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.93) EPS, Q1 2025 earnings at ($0.14) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.17 EPS and FY2025 earnings at $0.07 EPS.
Other analysts have also recently issued research reports about the stock. HC Wainwright reduced their price objective on shares of Esperion Therapeutics from $22.00 to $16.00 and set a "buy" rating on the stock in a research note on Wednesday, February 28th. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday, February 27th. Finally, Bank of America cut shares of Esperion Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, January 3rd. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $9.33.
View Our Latest Analysis on ESPR
Esperion Therapeutics Stock Down 3.7 %
Shares of NASDAQ ESPR traded down $0.08 during midday trading on Thursday, reaching $2.11. 4,541,501 shares of the company were exchanged, compared to its average volume of 5,709,105. The stock's 50-day moving average price is $2.41 and its 200-day moving average price is $1.76. The stock has a market cap of $390.46 million, a P/E ratio of -1.00 and a beta of 0.82. Esperion Therapeutics has a one year low of $0.70 and a one year high of $3.34.
Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.03. The firm had revenue of $32.25 million for the quarter, compared to analyst estimates of $26.84 million. During the same quarter in the prior year, the firm earned ($0.76) earnings per share.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the business. Chicago Partners Investment Group LLC bought a new stake in Esperion Therapeutics in the third quarter worth $29,000. Simplicity Solutions LLC purchased a new stake in Esperion Therapeutics in the third quarter worth about $30,000. Private Portfolio Partners LLC bought a new position in shares of Esperion Therapeutics in the fourth quarter worth approximately $30,000. Sei Investments Co. lifted its stake in shares of Esperion Therapeutics by 78.7% in the first quarter. Sei Investments Co. now owns 20,979 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 9,242 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Esperion Therapeutics by 199.7% during the first quarter. Tower Research Capital LLC TRC now owns 20,907 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 13,932 shares during the period. 69.76% of the stock is currently owned by hedge funds and other institutional investors.
Esperion Therapeutics Company Profile
(
Get Free Report)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Read More
Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
